Clinical trials: Immunotherapy
Peanut Allergy
Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)
Primary objective is to assess whether dupilumab as adjunct to AR101 compared to placebo improves desensitization at the completion of up-dosing, defined as an increase in the proportion of participants who pass a post up-dosing…
- Trial name
- NCT03682770
- Testing
- Dupilumab, AR101
- Where
- 25 sites in United States
- Volunteers
- 148 people
- Sponsor
- Regeneron Pharmaceuticals
Synovial Sarcoma, Cancer
A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)
To assess if the CMB305 vaccine regimen may help the body's immune system to slow or stop the growth of synovial sarcoma tumor and improve survival.
- Conditions
- Synovial Sarcoma, Cancer, Soft Tissue Sarcoma, Sarcoma
- Trial name
- NCT03520959
- Testing
- LV305, G305
- Where
- 29 sites in United States, Canada
- Volunteers
- 1 people
- Sponsor
- Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
This is an open-label, multicenter, phase 2 clinical trial to evaluate the efficacy and safety of brentuximab vedotin as a single agent in patients with CD30-positive non-Hodgkin lymphoma (NHL) (Part A).
- Conditions
- Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell
- Trial name
- NCT01421667
- Testing
- brentuximab vedotin, rituximab
- Where
- 34 sites in United States, Canada
- Volunteers
- 176 people
- Sponsor
- Seagen Inc.
Rhinitis, Allergic, Rhinoconjunctivitis
Study to Evaluate the Efficacy and Safety of "Allergovac Poliplus" in Polysensitized Patients With Allergic Rhinitis/Rhinoconjunctivitis, With or Without Asthma
This is an observational prospective multicenter clinical study, to evaluate the efficacy and safety of the treatment with Allergovac Poliplus subcutaneous immunotherapy (SCIT) with a mixture of 2 allergenic extracts (pollens or…
- Trial name
- ARES (NCT03821077)
- Testing
- Allergen Immunotherapy (AIT)
- Where
- 10 sites in Spain
- Volunteers
- 122 people
- Sponsor
- Roxall Medicina España S.A
Acute Myeloid Leukemia
ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia
This is a single-center open-label phase I clinical trial of delivering haploidentical natural killer (NK) cells matured ex vivo with ALT-801 followed by intravenous infusions of ALT-801 in patients with relapsed/refractory Acute…
- Trial name
- NCT01478074
- Testing
- G-CSF, Cytarabine, Fludarabine
- Where
- United States
- Sponsor
- Altor BioScience
Peanut Allergy
Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT
This is a multi-center, randomized, double-blind placebo controlled study of efficacy and safety of characterized peanut oral immunotherapy in peanut allergic individuals.
- Trial name
- ARC001 (NCT01987817)
- Testing
- AR101 powder provided in capsules
- Where
- 8 sites in United States
- Volunteers
- 56 people
- Sponsor
- Aimmune Therapeutics, Inc.
Cutaneous Metastatic Melanoma
Intratumoral Targeted Hyperthermia Therapy (THT) for Cutaneous Metastatic Melanoma
This device phase I/II, first in human, early feasibility study (EFS), open-label, single-arm trial aims to evaluate the safety, tolerability, and preliminary efficacy of Gold Nanorod (GNR)-enabled sub-ablative targeted…
- Trial name
- NCT06870994
- Testing
- Targeted Hyperthermia Therapy
- Volunteers
- 10 people
- Sponsor
- Sona Nanotech Inc
Peanut Allergy
Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Children
The objectives of this open-label follow-up study for subjects who previously were randomized and have completed the VIPES study for the treatment of peanut allergy, are: To assess the efficacy of Viaskin Peanut after up to 36…
- Trial name
- OLFUS-VIPES (NCT01955109)
- Testing
- Viaskin Peanut 250 mcg
- Where
- 22 sites in United States, Canada and 2 more
- Volunteers
- 171 people
- Sponsor
- DBV Technologies
Allergic Rhinoconjunctivitis
Multicenter Trial of Sublingual Immunotherapy With a Solution of Grass Pollen Allergen Extract in Children
Evaluation of safety and efficacy of sublingual immunotherapy with grass pollen allergens formulated as solution in comparison to a symptomatic standard treatment with add on placebo in grass pollen allergic children suffering…
- Trial name
- NCT00841256
- Testing
- Grass pollen allergens in a water/glycerol solution
- Where
- Germany
- Volunteers
- 207 people
- Sponsor
- Allergopharma GmbH & Co. KG
Lymphoma Leukemia
Immunotherapy With CD19 CAR T-cells in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma
B cell malignancies comprise a heterogeneous group of neoplasms including a vast majority of non-Hodgkin's lymphomas (NHL), lymphoblastic leukemias (ALL) and chronic lymphocytic leukemias (CLL).
- Trial name
- NCT03811457
- Testing
- Welgenaleucel
- Where
- China
- Volunteers
- 9 people
- Sponsor
- UWELL Biopharma
Rhinitis, Rhinoconjunctivitis
Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy
The purpose of the study is to evaluate the more efficient dose for the treatment of rhinitis/rhinoconjunctivitis against mite allergy
- Trial name
- MM09 (NCT02661854)
- Testing
- MM09 Mannosylated 5.000 subcutaneous, MM09 Mannosylated 10.000 subcutaneous, MM09 Mannosylated 30.000 subcutaneous
- Where
- 14 sites in Spain
- Volunteers
- 186 people
- Sponsor
- Inmunotek S.L.
Allergy
Observational Study of Oralair® in Children 5-9 Years With Grass-pollen-induced Allergic Rhinitis With/Without Conjunctivitis
Safety and tolerability of ORALAIR in children 5 to 9 years of age during the first 30 days of treatment.
- Trial name
- NCT02295969
- Testing
- Oralair
- Where
- Germany
- Volunteers
- 307 people
- Sponsor
- Stallergenes Greer
Rhinitis, Allergic, Rhinoconjunctivitis
Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen
Prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial of efficacy and safety with subcutaneous immunotherapy in patients with mild to moderate rhinitis / rhinoconjunctivitis with or without mild to…
- Conditions
- Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic
- Trial name
- NCT04891237
- Testing
- 10,000 MG01 + 10,000 T517, 30,000 MG01 + 10,000 T517
- Where
- 32 sites in Spain
- Volunteers
- 180 people
- Sponsor
- Inmunotek S.L.
Allergic Asthma
Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma
The purpose of this study is to determine whether a short course of subcutaneous immunotherapy is efficacious in mite induced asthma. The efficacy is based on reduction in control medication.
- Trial name
- NCT00492076
- Testing
- Pangramin Plus D. pteronyssinus 100%
- Where
- Spain
- Volunteers
- 45 people
- Sponsor
- ALK-Abelló A/S
Allergic Rhinoconjunctivitis
A Survey of Adults and Children With Allergic Rhinoconjunctivitis (MK-7243-021)
This study will gather information on allergic rhinoconjunctivitis from surveys completed by adults and children.
- Trial name
- AIRS (NCT01535118)
- Volunteers
- 2,765 people, healthy volunteers welcome
- Sponsor
- ALK-Abelló A/S
Solid Tumor
Autologous Tumour Vaccine Trial
Phase 1 trial to evaluate the feasibility of preparation, safety, tolerability and response to a personalised autologous tumour vaccine (ATV) formulated with Advax adjuvant when administered to patients with advanced solid…
- Trial name
- NCT05807035
- Testing
- Radvax
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- Vaxine Pty Ltd
Neoplasms
Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)
The cell behavior that the investigators regard as "malignant," including: cell autonomy; invasion and digestion of surrounding normal tissues; migration and colonization of distant organs; ability to develop resistance to drugs…
- Trial name
- NCT02366884
- Testing
- Anti-Bacterial Agents, Anti-Fungal Agents, Anti-Protozoal Agents
- Where
- 2 sites in Mexico
- Volunteers
- 250 people
- Sponsor
- Dr. Frank Arguello Cancer Clinic
Ewing's Sarcoma, Ewing Family of Tumors
Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma
The purpose of this study is to determine the safety and the maximum tolerated dose of of pbi-shRNA™ EWS/FLI1 Type 1 lipoplex in patients with advanced Ewing's sarcoma.
- Conditions
- Ewing's Sarcoma, Ewing Family of Tumors, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic
- Trial name
- NCT02736565
- Testing
- pbi-shRNA™ EWS/FLI1 Type 1 Lipoplex
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Gradalis, Inc.
Peanut Allergy
Viaskin® Peanut (DBV712) Expanded Access Protocol
This is an open label expanded access program for male and female patients ≥ 4 years old.
- Trial name
- NCT04371627
- Testing
- Viaskin Peanut
- Sponsor
- DBV Technologies
B-cell Acute Lymphoblastic Leukemia, Lymphoma
Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Lymphoma, Myeloid Leukemia, Multiple Myeloma
- Trial name
- NCT03638206
- Testing
- CAR-T cell immunotherapy
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Shenzhen BinDeBio Ltd.